Compare GLBS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | ITRM |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Greece | Ireland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 24.3M |
| IPO Year | 2007 | 2018 |
| Metric | GLBS | ITRM |
|---|---|---|
| Price | $1.75 | $0.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | 278.3K | ★ 1.3M |
| Earning Date | 11-28-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,444,000.00 | $390,000.00 |
| Revenue This Year | $16.13 | N/A |
| Revenue Next Year | $20.15 | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $0.99 | $0.36 |
| 52 Week High | $1.99 | $3.02 |
| Indicator | GLBS | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 44.75 |
| Support Level | $1.72 | $0.44 |
| Resistance Level | $1.99 | $0.48 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 70.24 | 53.35 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.